Article: Novartis Launches Z-FAST: A Study Evaluating Femara(R) and Zometa(R) in Postmenopausal Women with Early Breast Cancer.

* Study of 500 women combines Femara, a leading aromatase inhibitor, with Zometa, the most widely used IV bisphosphonate * Z-FAST will evaluate adjuvant cancer treatment-related bone loss in postmenopausal women with early breast cancer

Novartis announced today that it is combining two widely used drugs in a trial to evaluate bone loss associated with cancer treatment in postmenopausal women with early breast cancer. The Novartis drugs being paired are Femara(R) (letrozole tablets), a leading aromatase inhibitor in advanced breast cancer, and Zometa(R) (zoledronic acid for injection), the most widely used IV bisphosphonate in treating bone complications of ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!